RNS Number: 1507 Z Tissue Regenix Group PLC 16 September 2020 TR-1: S tandard form for notification of major holdings. This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom.
RNS Number: 9551 Y Tissue Regenix Group PLC 14 September 2020 TR-1: S tandard form for notification of major holdings. This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom.
Leeds, 2 September 2020- Tissue Regenix Group the regenerative medical devices company today announces its unaudited interim results for the six months to 30 June 2020.. ·Group revenues of £6.1 m. ·Cash position of £13.7 m following successful equity fundraise of £13.8 m completed in June 2020..
RNS Number: 2631 X Tissue Regenix Group PLC 27 August 2020 Tissue Regenix Group plc. Leeds, 27 August 2020- Tissue Regenix Group the regenerative medical devices company today gives notice that it will announce its unaudited interim results for the six months ending 30 th June 2020, on Wednesday 2 nd September 2020.. Tissue Regenix was formed in 2006 when it was...
UK distribution partner for OrthoPure ® XT. Leeds, UK, 24 August 2020- Tissue Regenix Group, the regenerative medical devices company, announces it has entered into a distribution agreement and secured its first order with a speciality supplier of orthopaedic and biologic products, for the UK distribution of OrthoPure ® XT, following its recent CE Mark...
RNS Number: 4706 W Tissue Regenix Group PLC 18 August 2020 TR-1: S tandard form for notification of major holdings. This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom.
Relocation of UK head office and manufacturing facility. Leeds, UK, 17 August 2020- Tissue Regenix Group, the regenerative medical devices company, announces the relocation of the Company's UK head office and manufacturing facilities to Garforth, Leeds, in November 2020.. The strategic decision to relocate the Company's UK operations from nearby Swillington,...
RNS Number: 1631 U Tissue Regenix Group PLC 27 July 2020 TR-1: S tandard form for notification of major holdings. This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom.
RNS Number: 9489 T Tissue Regenix Group PLC 24 July 2020 Tissue Regenix Group plc. Commencement of facility expansion plan. Leeds, 24 July 2020- Tissue Regenix Group, the regenerative medical devices company, announces that following the recent completion of its successful fundraising, the Company has commenced the first phase of its planned manufacturing...
RNS Number: 9467 T Tissue Regenix Group PLC 23 July 2020 TR-1: S tandard form for notification of major holdings. i Please note that national forms may vary due to specific national legislation as for instance the applicable thresholds or information regarding capital holdings.. Indicate in the relevant section whether the issuer is a non UK issuer..
RNS Number: 3462 T Tissue Regenix Group PLC 17 July 2020 TR-1: S tandard form for notification of major holdings. This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom.
RNS Number: 7174 S Tissue Regenix Group PLC 10 July 2020 TR-1: S tandard form for notification of major holdings. This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom.
RNS Number: 1219 S Tissue Regenix Group PLC 06 July 2020 TR-1: S tandard form for notification of major holdings. This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom.
RNS Number: 9855 R Tissue Regenix Group PLC 03 July 2020 TR-1: S tandard form for notification of major holdings. This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom.
Leeds, 30 June 2020- Tissue Regenix Group the regenerative medical devices company, provides notification that the number of ordinary shares of 0.1 pence in issue and number of voting rights is 7,032,985,756.. Tissue Regenix was formed in 2006 when it was spun-out from the University of Leeds, UK. In November 2012 Tissue Regenix Group plc set up a subsidiary...
RNS Number: 5249 R Tissue Regenix Group PLC 30 June 2020 Tissue Regenix Group plc. Leeds, 30 June 2020- Tissue Regenix Group the regenerative medical devices company, provides notification that, at the Group's AGM held earlier today, all resolutions were duly proposed to shareholders and passed. Tissue Regenix was formed in 2006 when it was spun-out from the...
RNS Number: 8323 Q Tissue Regenix Group PLC 23 June 2020 Tissue Regenix Group Plc. PDMR dealing and issue of equity. Leeds, 23 June 2020- Tissue Regenix Group plc, the regenerative medical devices company, announces the exercise of options by Shervanthi Homer-Vanniasinkam, a Non-Executive Director.
RNS Number: 2677 Q Tissue Regenix Group PLC 17 June 2020 TR-1: S tandard form for notification of major holdings. This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom.
RNS Number: 9761 P Tissue Regenix Group PLC 15 June 2020 TR-1: S tandard form for notification of major holdings. This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom.
RNS Number: 7263 P Tissue Regenix Group PLC 11 June 2020 TR-1: S tandard form for notification of major holdings. This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom.
Bid
-
-
-
Ask
  • High
    -
  • OPEN
    -
  • VOL
    -
  • MKT CAP
    -m
  • LOW
    -
  • CLOSE
    -
  • AVG VOL
    -
  • SHARES IN ISSUE
    1.17B

Company Profile

Tissue Regenix Group is a pioneering, international medical technology company, focusing on the development of regenerative products

Classification

Market Indices-
Watchlist